Radio-Labelled Antibodies: Big Benefits in Follicular Lymphoma?

Timothy Illidge

Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
TIMOTHY ILLIDGE, Christie Hospital, Manchester
Radioconjugated antibodies are showing great promise for treating follicular lymphoma which has failed chemotherapy combined with rituximab. That’s according to Tim Illidge who told the Paris conference that tositumomab and ibritumomab tiuxetan have already proved effective. He explained to Peter Goodwin why he thinks the latest data look promising.